Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Pleural effusion

ABSTRACT: Pleural effusion Raw sequence reads

PROVIDER: PRJNA692057 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13569269_1.fastq.gz	Fastqsanger.gz
	SRR13569270_1.fastq.gz	Fastqsanger.gz
	SRR13569271_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 3 of 3

Similar Datasets

Microarray expression profiles of circular RNA in malignant pleural effusion

Project description:To explore the expression pattern of circular RNAs (circRNAs) and their biological functions in malignant pleural effusion, we surveyed the circRNA expression profiles of 3 lung adenocarcinoma-associated malignant pleural effusion (LA-MPE) and 3 tuberculous pleural effusion (TPE) from clinical patients using Clariom D human microarray.

2023-05-01 | GSE122427 | GEO

Human pleural effusion LC-MSMS

Project description:We screened pleural effusion proteomes of mesothelioma and lung adenocarcinoma patients to identify novel soluble mesothelioma biomarkers. We performed quantitative mass spectrometry-(MS-) based proteomics using isobaric tags for relative and absolute quantification (iTRAQ) and used narrow range immobilized pH gradient/high resolution isoelectric focusing (IPG/HiRIEF; pH 4 to 4.25) prior to analysis by nano liquid chromatography-coupled MS/MS. Pleural effusions from patients with malignant mesothelioma (n=6), lung adenocarcinoma (n=6), or benign mesotheliosis (n=7) were analyzed, and more than 1,300 proteins were identified.

2014-01-14 | PXD000531 | Pride

Quantitative proteomics revealed novel protein biomarkers to distinguish malignant pleural effusion from benign pleural effusion

Project description:A four-dimensional independent data acquisition (4D-DIA) proteomic was performed to determine the differentially expressed proteins in pleural effusion samples collected from ung adenocarcinoma MPE, BPE (tuberculosis pleural effusion (TPE) and parapneumonic effusion (PPE)).

2024-03-08 | PXD050477 |

CircRNA_051778 in Exosomes as A Potential Biomarker for Distinguishing Lung Adenocarcinoma-Associated Malignant Pleural Effusion from Tuberculous Pleural Effusion

Project description:We profiled the exosomal circRNA in lung adenocarcinoma-associated malignant (LA-MPE) and tuberculous (TPE) pleural effusion samples by circRNA microarray to determine the potential functions and diagnostic value of the differential expressed circRNAs (DECs)

2022-04-01 | GSE171540 | GEO

Expression of miRNA in exosomes from transudative pleural effusion and tuberculous pleural effusions

Project description:Pleural fibrosis is defined as an excessive deposition of extracellular matrix (ECM) that results in destruction of the normal pleural tissue architecture and compromised function. However there is currently no effective medication for pleural fibrosis. Understanding the detailed mechanisms of pleural fibrosis is an important unmet need which could lead to the identification of new targets for treatment of this condition. microRNAs (miRNAs) play an important role in the posttranscriptional control of gene expression. In our study, cellular fractions from TBPE contained activities capable of promoting fibrosis-like behavior in pleural mesothelial cells (PMCs), the goal of this study is to compare the exosomal miRNA composition of TBPE and TPE. We isolated exosomes from transudative pleural effusion and tuberculous pleural effusions and performed miRNA sequencing. Our study represents the first detailed analysis of exosomal miRNA composition of TBPE and TPE with biologic replicates, generated by miRNA-Seq technology.

2024-04-14 | GSE172150 | GEO

Unbiased undepleted malignant pleural effusion proteomics study

Project description:Pleural effusion (PE) occurs as a consequence of various pathologies. Malignant effusion due to lung cancer is one of the most frequent causes. Methods for accurate differentiation of malignant from benign PE cases are an unmet clinical need. Proteomics profiling of PE has shown promising results. However, mass spectrometry (MS) analysis typically involves the tedious elimination of abundant proteins before analysis, and clinical annotation of proteomics profiled cohorts is limited. In this study, PE from 97 patients was investigated by applying label-free state-of-the-art liquid chromatography-mass spectrometry (LC-MS) to find potential novel biomarkers that correlate with immunohistochemistry assessment of tumor biopsy or survival data. The data set consists of 214 LC-MS runs.

2022-10-14 | PXD035884 | Pride

Single-cell sequencing of pleural effusion reveals immune response of COV2019 infection

Project description:Single-cell sequencing of pleural effusion reveals immune response of COV2019 infection

2023-03-12 | GSE146943 | GEO

The RNA Sequencing of B Cells in malignant pleural effusion

Project description:By using RNA sequencing plat, we employed malignant pleural effusion as research model to performed RNA sequencing of naïve B cells and Breg cells in the immune microenvironment of MPE.

2022-12-14 | GSE220822 | GEO

Survival and pleurodesis response markers in malignant pleural effusion – The PROMISE study

Project description:Background: Malignant pleural effusion (MPE) is a common condition that indicates advanced malignancy, incurability and short life expectancy. While MPE incidence is increasing worldwide, prognostic biomarkers to plan treatment and to understand the underlying mechanisms of disease progression remain unidentified. Objective: To discover, validate, and prospectively assess biomarkers of survival and pleurodesis response in MPE. To combine clinical, radiologic, and pleural fluid biologic parameters in order to build a score that forecasts survival. Conclusions: The PROMISE score is the first prospectively validated prognostic model for MPE that combines biological and clinical parameters to accurately estimate 3-month mortality.

2018-07-17 | PXD008682 | Pride

Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in non-small cell lung cancer patients with intestinal lung disease. A multicenter non randomized trial.

Project description:Interventions: Multicenter, single-arm, open-label trial Primary outcome(s): The pleural effusion control rate (30days after administration of hypotonic cisplatin for malignant pleural effusion) Study Design: Single arm Non-randomized

| 2638358 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data